GMI Research expects the global Artificial Pancreas Market was USD XX million in 2018 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of 15.0% during 2018–2026.
Artificial pancreas is a device specially designed to release insulin according to the changes in the blood glucose levels. An artificial pancreas device monitors glucose level in the body, automatically adjusts the delivery of insulin to reduce high blood glucose levels and minimizes the incidence of low blood glucose.

To have an edge over the competition by knowing the market dynamics and current trends of “Artificial Pancreas Market”, request for Sample Report here

The Global Artificial Pancreas market is primarily driven by the increasing incidences of diabetes patients, growing awareness among the patients about the disease, innovations and technological advancement in diabetes care devices, increasing patients’ disposable income and government insurance coverage. Furthermore, increasing adoption of artificial pancreas at hospitals, rising technological advancement and spending on healthcare facilities across the globe will drive growth of the diabetes care devices over the forecast period.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Hybrid device type is anticipated to lead the market during 2019-2026 due to the growing innovations and technological advancement in insulin monitoring and delivery technology. Bi Hormonal product type is projected to grow at a higher growth rate during the forecast period owing to the increasing adoption of Bi Hormonal artificial pancreas among healthcare professionals and patients due to its numerous remarkable benefits such as technological advanced properties.

Hospital segment is expected to grow at a highest CAGR during the forecast period owing to the continuous advancements in diabetes care industry, increasing prevalence rate of diabetes disease and the increasing research & development activities. Artificial Pancreas is a disruptive product in the field of diabetes care devices as it offers continuous monitoring of insulin in the blood and auto delivery of insulin to reduce high blood glucose level. Moreover, the improved healthcare infrastructure and presence of skilled doctors will further boost the demand of the Artificial Pancreas market over the coming years.

Players, such as Abbot Laboratories, Medtronic and Boston Scientific Corporation are hugely investing in the research & development activities. The companies are focusing on continuous product innovation in order to capture higher market share in the Artificial Pancreas Market. For instance, more than 7 products are in clinical pipelines phase for diabetes disease across the globe.

In case, any of your paint points areas are not covered in the current scope of this report, Request for Customization here

North America captured the largest market share in the Global Artificial Pancreas Market in 2018 owing to increasing government and private funding on healthcare infrastructure, rising diagnosis rate of diabetes and growing incidences of diabetic patients. Asia pacific is expected to grow at a higher CAGR during the forecast years owing to the rising number of patients suffering from diabetes caused by the changing lifestyle, genetic drift or modification, growing urbanization and aging factor. Over the forecast years escalating incidences of diabetes disease is anticipated to sustain market growth. As per NCBI published article, Asia-Pacific countries contribute to approximately more than 60% to the global diabetic population, supporting the growth of the artificial pancreas market in the region during the forecast period.

Major key players in the Global Artificial pancreas market include Abbott Laboratories, Becton Dickinson and Company, Bayer Healthcare, Roche Holding AG, Medtronic plc, Dexcom Inc, Biotronik SE & GlaxoSmithKline and others.

Key Market Developments:

• • In Dec 2019, Tandem Diabetes care announced the FDA approval of one of its kind Insulin pump t slim X2 Insulin Pump to strengthen the roots in the Insulin Delivery Device market.
  • Abbott and Big Foot medical collaborated to develop and promote the diabetes management systems, further advancing Abbott’s freestyle libra glucose sensing tech to strengthen their Insulin Delivery Segment in United States.

The global artificial pancreas market has been segmented based on product type, end user and key geographies. Based on product type, the market comprises of insulin, bi-Hormonal and hybrid. The end-user segment includes clinics, hospitals and others and key geographical regions.

For detailed scope of the “Artificial Pancreas Market” report request a Sample Copy of the report

Key questions answered in this research report:

• • At what pace is artificial pancreas market growing? What will be the growth trend in future?
  • What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the coming years?
  • What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in the artificial pancreas market?
  • What are the various product types and how they are poised to grow?
  • What companies are the major participants in this market and their business strategies, how does the competitive landscape look like?

Report Coverage	Details
Market Base Year	2018
Market Forecast Period	2019-2026
Market Revenues Currency	USD Million
Base Year & Forecast Units	Value (USD Million)
Market Segment	By Product Type, By End User, By Region
Regional Coverage	Asia Pacific, Europe, North America, and RoW
Companies Profiled	Tandem Life Sciences, Becton Dickinson and Company, Bayer Healthcare, Roche Holding AG, Medtronic plc, Dexcom Inc, Biotronik SE & GlaxoSmithKline and among others. A total of 10 companies have been covered in the report
25% Free Customization Available	We will customize this report up to 25% as a free customization to address our client’s specific requirements

Market Segmentation:

By Product Type

• • Insulin
  • Bi-Hormonal
  • Hybrid

By End User Type

• • Hospitals
  • Clinics
  • Others

By Geography

• • North America
    Option 1: As a part of the free 25% customization
    • By Product type
    • By End User Type
    • United States All-Up
    • Canada All-Up
  • Europe
    Option 2: As a part of the free 25% customization
    • By Product type
    • By End User Type
    • UK All-Up
    • Germany All-Up
    • Spain All-Up
    • Rest of Europe
  • Asia-Pacific
    Option 3: As a part of the free 25% customization
    • By Product type
    • By End User Type
    • China All-Up
    • Australia All-Up
    • India All-Up
    • Rest of APAC
  • ROW
    Option 4: As a part of the free 25% customization
    • By Product type
      • By End User Type
      • Brazil All-Up
      • South Africa All-Up
      • GCC countries All-Up
      • Rest of world (remaining countries of the LAMEA region)

Leading market players (Option 5: As a part of the free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • Abbott Laboratories
  • Becton Dickinson and Company
  • Bayer Healthcare
  • Roche Holding AG
  • Medtronic plc
  • Dexcom Inc
  • Biotronik SE
  • GlaxoSmithKline